{"id":55338,"date":"2023-03-30T08:03:29","date_gmt":"2023-03-30T06:03:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/"},"modified":"2023-03-30T08:03:29","modified_gmt":"2023-03-30T06:03:29","slug":"sensorion-announces-the-publication-of-its-2022-annual-financial-report","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/","title":{"rendered":"Sensorion Announces the Publication of Its 2022 Annual Financial Report"},"content":{"rendered":"<div>\n<p>MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p>\n<b>Sensorion (FR0012596468 \u2013 ALSEN) <\/b>a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority (AMF).\n<\/p>\n<p>\nThe 2022 Annual Financial Report includes:\n<\/p>\n<ul class=\"bwlistsquare\">\n<li>\nThe Management Report\n<\/li>\n<li>\nThe Annual Accounts and the Financial Statements\n<\/li>\n<li>\nThe information on fees paid to the Statutory auditors of the 2022 accounts\n<\/li>\n<\/ul>\n<p>\nThe Annual Financial Report can be found on:\n<\/p>\n<ul class=\"bwlistsquare\">\n<li>\nSensorion\u2019s website (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sensorion.com&amp;esheet=53370619&amp;newsitemid=20230329005836&amp;lan=en-US&amp;anchor=www.sensorion.com&amp;index=1&amp;md5=3c8447638e0fc8c80a5e2cf56e03f7b5\" rel=\"nofollow noopener\" shape=\"rect\">www.sensorion.com<\/a>), in the Financial Information section\n<\/li>\n<li>\nThe AMF\u2019s website (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=53370619&amp;newsitemid=20230329005836&amp;lan=en-US&amp;anchor=www.amf-france.org&amp;index=2&amp;md5=eaed8a109590ae86afa95bff11c7363e\" rel=\"nofollow noopener\" shape=\"rect\">www.amf-france.org<\/a>)\n<\/li>\n<\/ul>\n<p>\nThe report is made available to the public, on request and free of charge, at the Company\u2019s Headquarters, located at 375, rue du Professeur Joseph Blayac, 34080, Montpellier, France.\n<\/p>\n<p>\n<b>About Sensorion<\/b>\n<\/p>\n<p>\nSensorion is a pioneering clinical-stage biotech company, which specializes in the development of gene therapies to restore hearing loss disorders, a significant global unmet medical need.\n<\/p>\n<p>\nSensorion has built a unique R&amp;D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.\n<\/p>\n<p>\nIt has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. OTOF-GT targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in <i>GJB2<\/i> gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.\n<\/p>\n<p>\nSensorion\u2019s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders.\n<\/p>\n<p>\nSensorion\u2019s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sensorion.com&amp;esheet=53370619&amp;newsitemid=20230329005836&amp;lan=en-US&amp;anchor=www.sensorion.com&amp;index=3&amp;md5=2147bf3eeeaeb45d826e663172ddce93\" rel=\"nofollow noopener\" shape=\"rect\">www.sensorion.com<\/a>\n<\/p>\n<p>\nLabel: <b>SENSORION<br \/>\n<br \/><\/b>ISIN: <b>FR0012596468<br \/>\n<br \/><\/b>Mnemonic: <b>ALSEN<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2022 full year financial report published on March 30, 2023, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Relations<\/b><br \/>David Lawrence, Chief Financial Officer (US\/UK)<br \/>\n<br \/>No\u00e9mie Djokovic, Investor Relations and Communications (Europe\/France)<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#105;&#114;&#x2e;&#x63;on&#116;&#97;&#x63;&#x74;&#64;s&#101;&#x6e;&#x73;&#x6f;r&#105;&#111;&#x6e;&#x2d;&#x70;h&#97;&#114;&#x6d;&#x61;&#x2e;c&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">i&#114;&#46;&#x63;&#x6f;n&#116;&#97;&#x63;&#x74;&#x40;s&#101;&#110;&#x73;&#x6f;ri&#111;&#x6e;&#x2d;&#x70;h&#97;&#114;&#x6d;&#x61;&#46;c&#111;&#x6d;<\/a><\/p>\n<p><b>International Media Relations<\/b><br \/>Consilium Strategic Communications<br \/>\n<br \/>Matthew Cole\/Jessica Hodgson\/Sue Stuart<br \/>\n<br \/>+44 7593 572720<br \/>\n<br \/>+44 7561 424788<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x53;e&#x6e;s&#x6f;r&#x69;o&#110;&#x40;&#99;&#x6f;&#110;&#x73;&#105;&#x6c;&#105;&#x75;m&#x2d;c&#x6f;m&#x6d;s&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x53;&#101;&#110;s&#x6f;&#x72;&#105;o&#x6e;&#x40;&#99;on&#x73;&#105;&#108;i&#x75;&#x6d;&#45;c&#x6f;&#x6d;&#109;&#115;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority (AMF). The 2022 Annual Financial Report includes: &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55338","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sensorion Announces the Publication of Its 2022 Annual Financial Report - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensorion Announces the Publication of Its 2022 Annual Financial Report - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority (AMF). The 2022 Annual Financial Report includes: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T06:03:29+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sensorion Announces the Publication of Its 2022 Annual Financial Report\",\"datePublished\":\"2023-03-30T06:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/\"},\"wordCount\":616,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/\",\"name\":\"Sensorion Announces the Publication of Its 2022 Annual Financial Report - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-30T06:03:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensorion Announces the Publication of Its 2022 Annual Financial Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensorion Announces the Publication of Its 2022 Annual Financial Report - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/","og_locale":"en_US","og_type":"article","og_title":"Sensorion Announces the Publication of Its 2022 Annual Financial Report - Pharma Trend","og_description":"MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority (AMF). The 2022 Annual Financial Report includes: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-30T06:03:29+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sensorion Announces the Publication of Its 2022 Annual Financial Report","datePublished":"2023-03-30T06:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/"},"wordCount":616,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/","url":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/","name":"Sensorion Announces the Publication of Its 2022 Annual Financial Report - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-30T06:03:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-the-publication-of-its-2022-annual-financial-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sensorion Announces the Publication of Its 2022 Annual Financial Report"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55338"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55338\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}